ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Novelix Pharmaceuticals allotted 25,00,000 equity shares to promoter group entities following warrant conversion. This increased the promoter group stake from 36.42% to 39.35%.
Novelix Pharma approved a total equity raise of ₹74.34 Crore through a promoter warrant conversion and a non‑promoter preferential issue. The issue adds 4.5 million shares to its paid‑up capital.
Novelix Pharmaceuticals allotted 45,75,000 equity shares, raising approximately Rs. 11.90 Crore. This includes warrant conversions for promoters and a preferential issue to 16 non-promoter investors.
Novelix Pharmaceuticals allotted 9,50,000 equity shares to promoter group entities following warrant conversions. The ₹2.81 Crore equity infusion strengthens the company's capital base.
Novelix Pharmaceuticals promoters converted warrants into 1,50,000 equity shares on May 29, 2026. This conversion increases the total promoter voting shareholding to 2.09%.
Novelix Pharmaceuticals allotted 28,10,000 equity shares upon warrant conversion, receiving ₹4.22 Crore. This increases the company's paid-up equity capital to ₹23.90 Crore.